TY - JOUR T1 - Early childhood linear growth faltering in low- and middle-income countries JF - medRxiv DO - 10.1101/2020.06.09.20127001 SP - 2020.06.09.20127001 AU - Jade Benjamin-Chung AU - Andrew Mertens AU - John M Colford, Jr AU - Alan E Hubbard AU - Mark J van der Laan AU - Jeremy Coyle AU - Oleg Sofrygin AU - Wilson Cai AU - Anna Nguyen AU - Nolan N Pokpongkiat AU - Stephanie Djajadi AU - Anmol Seth AU - Wendy Jilek AU - Esther Jung AU - Esther O Chung AU - Sonali Rosete AU - Nima Hejazi AU - Ivana Malenica AU - Haodong Li AU - Ryan Hafen AU - Vishak Subramoney AU - Jonas Häggström AU - Thea Norman AU - Kenneth H. Brown AU - Parul Christian AU - Benjamin F. Arnold AU - members of the ki Child Growth Consortium Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/21/2020.06.09.20127001.abstract N2 - Globally 149 million children under five are estimated to be stunted (length more than 2 standard deviations below international growth standards). Stunting, a form of linear growth faltering, increases risk of illness, impaired cognitive development, and mortality. Global stunting estimates rely on cross-sectional surveys, which cannot provide direct information about the timing of onset or persistence of growth faltering— a key consideration for defining critical windows to deliver preventive interventions. We performed the largest pooled analysis of longitudinal studies in low- and middle-income countries to date (n=32 cohorts, 52,640 children, ages 0-24 months), allowing us to identify the typical age of linear growth faltering onset and to investigate recurrent faltering in early life. The highest incidence of stunting onset occurred from birth to age 3 months. From 0 to 15 months, less than 5% of children per month reversed their stunting status, and among those who did, stunting relapse was common. Early timing and low reversal rates emphasize the importance of preventive intervention delivery within the prenatal and early postnatal phases coupled with continued delivery of postnatal interventions through the first 1000 days of life.Competing Interest StatementThea Norman is an employee of the Bill & Melinda Gates Foundation (BMGF). Kenneth H Brown and Parul Christian are former employees of BMGF. Jeremy Coyle, Vishak Subramoney, Ryan Hafen, and Jonas Häggström work as research contractors funded by the BMGF.Funding StatementThis research was financially supported by a global development grant (OPP1165144) from the Bill & Melinda Gates Foundation to the University of California, Berkeley, CA, USA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Committee for Protection of Human Subjects at UC Berkeley determined that this analysis was exempt from review.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the Bill and Melinda Gates Foundation Knowledge Integration project upon reasonable request. ER -